Cocrystal Pharma Operating Income Over Time
| COCP Stock | USD 1.05 0.01 0.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cocrystal Pharma Performance and Cocrystal Pharma Correlation. Cocrystal | Build AI portfolio with Cocrystal Stock |
Can Pharmaceuticals industry sustain growth momentum? Does Cocrystal have expansion opportunities? Factors like these will boost the valuation of Cocrystal Pharma. Projected growth potential of Cocrystal fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cocrystal Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 0.269 | Return On Assets | Return On Equity |
Understanding Cocrystal Pharma requires distinguishing between market price and book value, where the latter reflects Cocrystal's accounting equity. The concept of intrinsic value - what Cocrystal Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cocrystal Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Cocrystal Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cocrystal Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cocrystal Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Cocrystal Pharma and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | 77.9 M | 1.3 B | 989 M | 1.2 B | 1.3 B | 1.7 B | 2 B | 1.7 B | 1.9 B | 2 B | 2.7 B | 2.8 B | 2.4 B | 3 B | 3.6 B | 4.2 B | 4.4 B |
| REGN | (3.3 M) | (205.2 M) | 457.7 M | 760 M | 838.4 M | 1.3 B | 1.3 B | 2.1 B | 2.5 B | 2.2 B | 3.6 B | 8.9 B | 5.4 B | 4 B | 4 B | 3.6 B | 3.8 B |
| IDXX | 2.6 M | 236.2 M | 262.6 M | 266.8 M | 260.3 M | 299.9 M | 350.2 M | 413 M | 491.3 M | 552.8 M | 694.5 M | 932 M | 898.8 M | 1.1 B | 1.1 B | 1.4 B | 1.4 B |
| HLN | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 897 M | 1.6 B | 1.6 B | 1.8 B | 2 B | 2.2 B | 2.5 B | 1.9 B |
| CI | (854.9 M) | 1.9 B | 2.9 B | 32.4 B | 11.6 B | 12.4 B | 3.1 B | 3.9 B | 4.2 B | 8.1 B | 8.2 B | 7.9 B | 8.4 B | 8.5 B | 9.4 B | 9.1 B | 9.6 B |
| ELV | 11.1 B | 4.5 B | 4.4 B | 4.7 B | 5.1 B | 5.4 B | 5.4 B | 5 B | 5.8 B | 6.7 B | 7.7 B | 8.9 B | 8.5 B | 8.7 B | 8.9 B | 8.1 B | 6.8 B |
| BDX | 137.7 M | 1.6 B | 1.3 B | 1.6 B | 1.1 B | 1.4 B | 1.5 B | 1.5 B | 1.8 B | 912 M | 2.2 B | 2.3 B | 2.1 B | 2.4 B | 2.6 B | 3 B | 3.1 B |
| ELAN | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 283.2 M | 142.4 M | 313.8 M | 370 M | (76.8 M) | 304 M | 384 M | 326 M | 251 M | 252 M | 255.5 M |
| ARGX | (4.7 M) | (4.7 M) | (13.3 M) | (8.6 M) | (13.1 M) | (17.1 M) | (22.5 M) | (27.5 M) | (93.6 M) | (198.9 M) | (477.6 M) | (348.7 M) | (720.3 M) | (425 M) | (21.7 M) | (19.5 M) | (20.5 M) |
| TAK | 171.4 B | 265 B | 122.5 B | 139.3 B | (129.3 B) | 130.8 B | 155.9 B | 241.8 B | 205 B | 100.4 B | 509.3 B | 460.8 B | 490.5 B | 214.1 B | 342.6 B | 308.3 B | 226.9 B |
Cocrystal Pharma and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Operating Income description
Operating Income is the amount of profit realized from Cocrystal Pharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cocrystal Pharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Cocrystal Pharma | COCP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 19805 North Creek |
| Exchange | NASDAQ Exchange |
USD 1.05
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.